AIRPORT CITY, Israel, Nov. 22, 2022 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced enrollment of a first patient to a phase 1/2 clinical trial designed to evaluate the safety and efficacy of its lead asset aspacytarabine (BST-236) in combination with the BCL2 inhibitor venetoclax for induction therapy of newly-diagnosed Acute Myeloid Leukemia (AML), followed by aspacytarabine single-agent consolidation therapy. The trial, conducted in leading clinical centers in the United States, enrolls newly-diagnosed AML patients who are unfit for standard induction chemotherapy due to age or comorbidities.
Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module.
Biosight Ltd., a pharmaceutical development company focused on the development of innovative therapeutics for hematological malignancies and...
AIRPORT CITY, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced final results for the primary study endpoint, complete remission (CR), from the Company’s Phase 2b clinical trial evaluating single-agent aspacytarabine (BST-236) as a first-line acute myeloid leukemia (AML) therapy for patients unfit for standard induction chemotherapy. These results, presented at the 2021 American Society of Hematology (ASH) Annual Meeting held in December, 2021, demonstrated efficacy, safety, and tolerability of BST-236 as a monotherapy in treatment of newly-diagnosed AML patients unfit for standard induction therapy.
AIRPORT CITY, Israel, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The multi-center study will be conducted across 18 leading U.S. and Israeli sites including Memorial Sloan Kettering Cancer Center and The University of Texas MD Anderson Cancer Center.
AIRPORT CITY, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today issued the following statement from its Chairman, Pini Orbach, PhD.
MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) issued a report on November 1, 2021, recommending that Advaxis stockholders vote “FOR” the merger of the Company with Biosight and recommends voting “FOR” all proposals, at the Company’s Special Meeting scheduled for November 16, 2021.
MONMOUTH JUNCTION, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the third quarter ended July 31, 2021 and provides a business update.
AIRPORT CITY, Israel, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The investigator sponsored trial will be led by Dr. Pierre Fenaux of the Groupe Francophone des Myélodysplasies (GFM), the French Study Group of the European Myelodysplastic Syndromes (MDS) Cooperative Group (EMSCO). GFM is a non-profit organization comprised of most French hematology centers that conducts and sponsors clinical trials and translational research and coordinates diagnostic and therapeutic guidelines for MDS.
MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction. The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine (BST-236). The combined company is expected to have approximately $50 million in cash, cash equivalents and marketable securities at closing. Following the closing, which is expected to occur in the second half of 2021, Advaxis will be renamed Biosight Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “BSTX”.